Tumor mutational load (TMB) [100], epidermal growth factor receptor (EGFR) mutations [101], and soluble programmed cell death ligand-1 (sPD-L1) [98] can predict response to immunotherapy. This evidence concerns the gene EGFR and neoplasm.